Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dabigatran Etexilate Polymorphs
NCT02171481Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2008
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 72 hours and Maximum measured concentration up to 72 hours. Started May 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02171481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171481.